Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) has been assigned a $10.00 price objective by equities researchers at J P Morgan Chase & Co in a report released on Monday. The firm currently has a “hold” rating on the specialty pharmaceutical company’s stock. J P Morgan Chase & Co’s price target suggests a potential downside of 42.43% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Jefferies Group LLC set a $18.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “buy” rating in a research report on Saturday, May 6th. Stifel Nicolaus reiterated a “buy” rating and set a $45.00 target price on shares of Valeant Pharmaceuticals International in a research report on Wednesday, May 10th. Vetr cut shares of Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.94 target price for the company. in a research report on Monday, May 15th. Guggenheim initiated coverage on shares of Valeant Pharmaceuticals International in a research report on Saturday, June 17th. They set a “buy” rating and a $18.00 target price for the company. Finally, BidaskClub upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a research report on Thursday, June 29th. Four analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and a consensus target price of $16.81.

Valeant Pharmaceuticals International (NYSE:VRX) traded down 1.146% during midday trading on Monday, hitting $17.171. The stock had a trading volume of 10,505,818 shares. The stock’s 50-day moving average is $13.59 and its 200-day moving average is $12.98. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.75. The company’s market cap is $5.97 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the consensus estimate of $0.87 by $1.93. The company had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The business’s revenue for the quarter was down 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.08) EPS. Equities analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) PT Set at $10.00 by J P Morgan Chase & Co” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/07/18/valeant-pharmaceuticals-international-inc-vrx-pt-set-at-10-00-by-j-p-morgan-chase-co.html.

In related news, Director Schutter Richard U. De purchased 20,000 shares of the stock in a transaction on Thursday, May 11th. The shares were purchased at an average cost of $13.90 per share, with a total value of $278,000.00. Following the acquisition, the director now directly owns 70,572 shares in the company, valued at $980,950.80. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 5.87% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gruss & Co. Inc. bought a new position in Valeant Pharmaceuticals International during the first quarter valued at $104,000. Financial Architects Inc boosted its position in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares in the last quarter. Harbor Advisors LLC bought a new position in Valeant Pharmaceuticals International during the first quarter valued at $110,000. WMS Partners LLC bought a new position in Valeant Pharmaceuticals International during the first quarter valued at $116,000. Finally, Brave Asset Management Inc. bought a new position in Valeant Pharmaceuticals International during the first quarter valued at $119,000. 50.45% of the stock is currently owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.